Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro

Infection and Immunity

Volumn 81, Issue 10, 2013, Pages 3894-3902

  Whitemarsh, Regina C M ^a   Tepp, William H ^a   Bradshaw, Marite ^a   Lin, Guangyun ^a   Pier, Christina L ^a   Scherf, Jacob M ^a   Johnson, Eric A ^a   Pellett, Sabine ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOTULISM; CELL ASSAY; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; FEMALE; FETUS; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOLOGICAL ASSAY; BOTULINUM TOXINS, TYPE A; CELLS, CULTURED; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; NEURONS; RATS;

EID: 84884384897     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00536-13     Document Type: Article

References (53)

1. PeckMW.2009. Biology and genomic analysis of Clostridium botulinum. Adv. Microb. Physiol. 55:183-265, 320.
2. Hill KK, Smith TJ. 2013. Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr. Top. Microbiol. Immunol. 364:1-20.
3. Giménez DF, Gimenez JA. 1995. The typing of botulinal neurotoxins. Int. J. Food Microbiol. 27:1-9.
4. Montal M. 2010. Botulinum neurotoxin: a marvel of protein design. Annu. Rev. Biochem. 79:591-617.
5. Montecucco C, Schiavo G. 1994. Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol. 13:1-8.
6. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, Sudhof TC, Niemann H, Jahn R. 1993. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365:160-163.
7. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K, Working Group on Civilian Biodefense. 2001. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059-1070.
8. Evidente VG, Adler CH. 2010. An update on the neurologic applications of botulinum toxins. Curr. Neurol. Neurosci. Rep. 10:338-344.
9. Truong DD, Stenner A, Reichel G. 2009. Current clinical applications of botulinum toxin. Curr. Pharm. Des. 15:3671-3680.
10. Schantz EJ, Johnson EA. 1992. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol. Rev. 56:80-99.
11. Dressler D. 2012. Clinical applications of botulinum toxin. Curr. Opin. Microbiol. 15:325-336.
12. Scott AB. 1980. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J. Pediatr. Ophthalmol. Strabismus 17: 21-25.
13. Dineen SS, Bradshaw M, Johnson EA. 2003. Neurotoxin gene clusters in Clostridium botulinum type A strains: sequence comparison and evolutionary implications. Curr. Microbiol. 46:345-352.
14. Willems A, East AK, Lawson PA, Collins MD. 1993. Sequence of the gene coding for the neurotoxin of Clostridium botulinum type A associated with infant botulism: comparison with other clostridial neurotoxins. Res. Microbiol. 144:547-556.
15. Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, Jackson PJ, Marks JD. 2007. Genetic diversity among Botulinum neurotoxin-producing clostridial strains. J. Bacteriol. 189:818-832.
16. Dover N, Barash JR, Arnon SS. 2009. Novel Clostridium botulinum toxin gene arrangement with subtype A5 and partial subtype B3 botulinum neurotoxin genes. J. Clin. Microbiol. 47:2349-2350.
17. Lúquez C, Raphael BH, Maslanka SE. 2009. Neurotoxin gene clusters in Clostridium botulinum type Ab strains. Appl. Environ. Microbiol. 75: 6094-6101.
18. Mazuet C, Ezan E, Volland H, PopoffMR, Becher F. 2012. Toxin detection in patients' sera by mass spectrometry during two outbreaks of type A botulism in France. J. Clin. Microbiol. 50:4091-4094.
19. Arndt JW, Jacobson MJ, Abola EE, Forsyth CM, Tepp WH, Marks JD, Johnson EA, Stevens RC. 2006. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J. Mol. Biol. 362:733-742.
20. Pier CL, Chen C, Tepp WH, Lin G, Janda KD, Barbieri JT, Pellett S, Johnson EA. 2011. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett. 585:199-206.
21. Torii Y, Kiyota N, Sugimoto N, Mori Y, Goto Y, Harakawa T, Nakahira S, Kaji R, Kozaki S, Ginnaga A. 2011. Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test. Toxicon 57:93-99.
22. Torii Y, Akaike N, Harakawa T, Kato K, Sugimoto N, Goto Y, Nakahira S, Kohda T, Kozaki S, Kaji R, Ginnaga A. 2011. Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats. J. Pharmacol. Sci. 117:275-285.
23. Tepp WH, Lin G, Johnson EA. 2012. Purification and characterization of a novel subtype a3 botulinum neurotoxin. Appl. Environ. Microbiol. 78: 3108-3113.
24. Schantz DJ, Kautter DA. 1978. Standardized assay for Clostridium botulinum toxins. J. Assoc. Off. Anal. Chem. 61:96-99.
25. Kalb SR, Lou J, Garcia-Rodriguez C, Geren IN, Smith TJ, Moura H, Marks JD, Smith LA, Pirkle JL, Barr JR. 2009. Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1,/A2, and/A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One 4:e5355. doi:10.1371/journal.pone.0005355.
26. Mazuet C, Dano J, PopoffMR, Creminon C, Volland H. 2010. Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity. PLoS One 5:e12416. doi:10.1371/journal.pone.0012416.
27. Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, Marks JD. 2005. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect. Immun. 73:5450-5457.
28. Pellett S, Tepp WH, Toth SI, Johnson EA. 2010. Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. J. Pharmacol. Toxicol. Methods 61:304-310.
29. Whitemarsh RC, Strathman MJ, Chase LG, Stankewicz C, Tepp WH, Johnson EA, Pellett S. 2012. Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicol. Sci. 126:426-435.
30. Pellett S, Tepp WH, Clancy CM, Borodic GE, Johnson EA. 2007. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett. 581:4803-4808.
31. Keller JE, Cai F, Neale EA. 2004. Uptake of botulinum neurotoxin into cultured neurons. Biochemistry 43:526-532.
32. Malizio CJ, Goodnough MC, Johnson EA. 2000. Purification of Clostridium botulinum type A neurotoxin. Methods Mol. Biol. 145:27-39.
33. Lin G, Tepp WH, Pier CL, Jacobson MJ, Johnson EA. 2010. Expression of the Clostridium botulinum A2 neurotoxin gene cluster proteins and characterization of the A2 complex. Appl. Environ. Microbiol. 76:40-47.
34. Jacobson MJ, Lin G, Tepp W, Dupuy J, Stenmark P, Stevens RC, Johnson EA. 2011. Purification, modeling, and analysis of botulinum neurotoxin subtype A5 (BoNT/A5) from Clostridium botulinum strain A661222. Appl. Environ. Microbiol. 77:4217-4222.
35. Bradshaw M, Marshall KM, Heap JT, Tepp WH, Minton NP, Johnson EA. 2010. Construction of a nontoxigenic Clostridium botulinum strain for food challenge studies. Appl. Environ. Microbiol. 76:387-393.
36. Heap JT, Pennington OJ, Cartman ST, Minton NP. 2009. A modular system for Clostridium shuttle plasmids. J. Microbiol. Methods 78:79-85.
37. Hatheway CL. 1988. Botulism, 111-133. In Balows A, Hausler WH, Ohashi M, Turano MA (ed), Laboratory diagnosis of infectious diseases: principles and practice, vol 1. Springer-Verlag, New York, NY.
38. Reed JL, Muench H. 1938. A simple method of determining fifty per cent endpoints. Am. J. Hyg. 27:493-497.
39. Henkel JS, Jacobson M, Tepp W, Pier C, Johnson EA, Barbieri JT. 2009. Catalytic properties of botulinum neurotoxin subtypes A3 and A4. Biochemistry 48:2522-2528.
40. Dong M, Tepp WH, Johnson EA, Chapman ER. 2004. Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc. Natl. Acad. Sci. U. S. A. 101:14701-14706.
41. Keller JE, Neale EA, Oyler G, Adler M. 1999. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. 456:137-142.
42. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER. 2006. SV2 is the protein receptor for botulinum neurotoxin A. Science 312:592-596.
43. Lacy DB, Stevens RC. 1999. Sequence homology and structural analysis of the clostridial neurotoxins. J. Mol. Biol. 291:1091-1104.
44. Breidenbach MA, Brunger AT. 2004. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432:925-929.
45. Jacky BP, Garay PE, Dupuy J, Nelson JB, Cai B, Molina Y, Wang J, Steward LE, Broide RS, Francis J, Aoki KR, Stevens RC, Fernandez-Salas E. 2013. Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A). PLoS Pathog. 9:e1003369. doi:10.1371/journal.ppat.1003369.
46. Cai S, Singh BR, Sharma S. 2007. Botulism diagnostics: from clinical symptoms to in vitro assays. Crit. Rev. Microbiol. 33:109-125.
47. Pellett S, Du ZW, Pier CL, Tepp WH, Zhang SC, Johnson EA. 2011. Sensitive and quantitative detection of botulinum neurotoxin in neurons derived from mouse embryonic stem cells. Biochem. Biophys. Res. Commun. 404:388-392.
48. Whitemarsh RC, Pier CL, Tepp WH, Pellett S, Johnson EA. 2012. Model for studying Clostridium botulinum neurotoxin using differentiated motor neuron-like NG108-15 cells. Biochem. Biophys. Res. Commun. 427:426-430.
49. McNutt P, Celver J, Hamilton T, Mesngon M. 2011. Embryonic stem cell-derived neurons are a novel, highly sensitive tissue culture platform for botulinum research. Biochem. Biophys. Res. Commun. 405:85-90.
50. Kiris E, Nuss JE, Burnett JC, Kota KP, Koh DC, Wanner LM, Torres-Melendez E, Gussio R, Tessarollo L, Bavari S. 2011. Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery. Stem Cell Res. 6:195-205.
51. Nuss JE, Ruthel G, Tressler LE, Wanner LM, Torres-Melendez E, Hale ML, Bavari S. 2010. Development of cell-based assays to measure botulinum neurotoxin serotype A activity using cleavage-sensitive antibodies. J. Biomol. Screen. 15:42-51.
52. Pellett S. 2013. Progress in cell based assays for botulinum neurotoxin detection. Curr. Top. Microbiol. Immunol. 364:257-285.
53. Fernández-Salas E, Wang J, Molina Y, Nelson JB, Jacky BP, Aoki KR. 2012. Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay. PLoS One 7:e49516. doi:10.1371/journal.pone.0049516